Pilot Trial of Selecting Molecularly-Guided Therapy for Patients with non-V600 BRAF Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team

Targeted therapies and immunotherapies have led to significant improvements in the treatment of advanced cancers, including metastatic melanoma. However, new strategies are desperately needed to overcome therapeutic resistance to these agents, as well as to identify effective treatment approaches fo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: LoRusso, Patricia M., Boerner, Scott A., Pilat, Mary Jo, Forman, Karen M., Zuccaro, Clarice Y., Kiefer, Jeffrey A., Liang, Winnie S., Hunsberger, Sally, Redman, Bruce G., Markovic, Svetomir N., Sekulic, Aleksandar, Bryce, Alan H., Joseph, Richard W., Cowey, C. Lance, Fecher, Leslie Anne, Sosman, Jeffrey Alan, Chapman, Paul B., Schwartz, Gary K., Craig, David W., Carpten, John D., Trent, Jeffrey M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5560131/
https://ncbi.nlm.nih.gov/pubmed/26063764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-15-0153
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados